Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Study of Trilaciclib prior to Sacituzumab in Patients with Triple Negative Breast Cancer

A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting

For more information:

https://clinicaltrials.gov/ct2/show/NCT05113966?term=Study+of+Trilaciclib+Administered+Prior+to+Sacituzumab+Govitecan-hziy+in+Patients&cond=Breast+cancer&draw=2&rank=1